Trial Profile
A Retrospective study to compare the safety and efficacy of 8 or 12 weeks of treatment with Ledipasvir/Sofosbuvir in treatment naive patients with non-cirrhotic genotype 1 Hepatitis C infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Oct 2018 New trial record
- 27 Sep 2018 Results published in the Digestive Diseases and Sciences